Amgen Rises Almost 22% YTD: Should You Buy, Hold or Sell the Stock?
AMGN's consistent top-line growth, an interesting pipeline and rising estimates are good enough reasons to stay invested in the stock for now.
GLP-1s are driving returns on R&D investments for Big Pharma, report says
Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular ...
Seeking Alpha27d
Amgen Stock: Why I Still Rate It A 'Buy'
In addition, the results showed that it has the potential to compete with Ozempic/Wegovy (semaglutide) and Mounjaro/Zepbound (tirzepatide). Amgen expects its revenue to be between $34.3 billion ...
BioSpace9d
GLP-1 Players Seek to Differentiate in Increasingly Crowded Weight Loss Space
As obesity drug developers compete for the highest weight-loss efficacy, experts contend that overall health ...
FierceBiotech15d
Novo Nordisk links CagriSema to 16% weight loss, sending stock down again
“It is our view that among investigated dual-acting agents (GLP-1/GIP, GLP-1/glucagon, GLP-1/amylin), the combination pursued by Eli Lilly’s Zepbound, Amgen’s MariTide, Viking’s VK2735 and ...
3 Magnificent Growth Stocks to Buy in March
It's often challenging to decide which stocks to invest in. However, some companies look too attractive to pass up. We asked three Motley Fool contributors to pick slam-dunk growth stocks investors ...
NBC Washington20d
Amgen starts two critical late-stage trials for weight loss drug MariTide
Amgen said it has started two critical late ... That's unlike Eli Lilly's obesity drug, Zepbound, which activates both GIP and GLP-1. Novo Nordisk's Wegovy activates GLP-1 but does not target ...
pharmaphorum5d
Amgen's big reveal of obesity data falls a little flat
Despite that assessment, shares in Amgen lost nearly 5% of their value ... better weight loss than Wegovy and roughly in line with Zepbound, which William Blair has now acknowledged is below ...